HLA-B*44:02 is associated with protection against multiple sclerosis in several studies (22–24), while, in the context of melanoma, carriage of the B*44 supertype has been associated with improved outcomes to ICB treatment (25), although this was not reproduced in a follow-up study (26). Here, PPIB is linked to melanoma.